Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
- Conditions
- Chronic Myelogenous Leukemia
- Registration Number
- NCT00041990
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Brief Summary
To determine the safety and efficacy of decitabine in patients with Philadelphia chromosome-positive chronic myelogenous leukemia accelerated phase that were previously treated with imatinib mesylate (STI 571) and became resistant/refractory or were found to be intolerant to the drug.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (8)
Metro-Minnesota CCOP
🇺🇸St. Louis Park, Minnesota, United States
Princess Margaret Hospital
🇨🇦Toronto, Ontario, Canada
New York Medical College
🇺🇸Valhalla, New York, United States
USC/Norris Cancer Center
🇺🇸Los Angeles, California, United States
University of Texas MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
City of Hope Medical Center
🇺🇸Duarte, California, United States
Scripps Clinic
🇺🇸Escondido, California, United States
Liberty Hematology/Oncology
🇺🇸Columbia, South Carolina, United States